Printer friendly
"AcronymAttic.com

What does E-NSCLC stand for?

E-NSCLC stands for extensive-disease non-small-cell lung cancer

This definition appears rarely

Samples in periodicals archive:

Extensive disease – This refers to small cell lung cancer.
Select Category -FAQ (8) General (105) GRACEcast (426) GRACE Cancer Video Library (36) GCVL-Lung (36) GRACEcasts Uncut (123) Case in Point (3) Webinars (109) Q & A (4) Lung Cancer (1,075) A Reference Library on Lung Cancer (51) ALK inhibition (33) Clinical Cases (31) Core Concepts (550) Bronchioloalveolar Carcinoma (BAC) (23) Early Stage NSCLC & Surgery (53) Immunotherapy (14) Liquid Biopsy (2) Locally Advanced (Stage III) NSCLC (91) Maintenance Therapy after First Line (47) Metastatic/Recurrent NSCLC (29) Metastatic/Recurrent NSCLC, First Line (59) Metastatic/Recurrent NSCLC, Second Line and Later (46) Never-Smokers with Lung Cancer (21) SCLC, Extensive Disease and Recurrent (24) SCLC, Limited Disease (17) Targeted Therapies, Activity and Side Effects (305) TNM Staging (1) What I Really Do (78) Current Clinical Trials (83) General Lung Cancer Issues (983) Causes of Lung Cancer & Prevention Strategies (28) Evaluation and Work-Up (142) Gene Profiles/Molecular Signatures (283) Imaging and Response Measurement (42) Management of Bone Metastases (5) Management of Brain Metastases (29) Management of Indolent Lung Cancers (1) Management of Pleural Effusions (8) Miscellaneous Other Problems from Lung Cancer (15) never-smoker NSCLC (51) Pathology/Lung Cancer Subtypes (96) Repeat Biopsies (3) Screening Issues and Controversy (36) Smoking Cessation/Tobacco Control (16) Supportive care (16) Treatment (786) Chemotherapy (248) Radiation therapy (85) PCI (2) SBRT (2) WBRT (2) Surgery Issues (83) Targeted therapies (559) ALK Inhibitors (44) Anti-angiogenic agents (63) BRAF Inhibitors (1) Epidermal growth factor receptor (EGFR)-based therapies (311) Clinical variables in EGFR therapy (68) EGFR mutations and other molecular markers (193) acquired resistance (16) Rash and other side effects (20) FDA Approval (5) HER2 Inhibitors (1) Immune/Vaccine-based therapies (56) Multikinase inhibitors (24) Other targeted therapies (72) PARP Inhibitors (3) VEGF (VEGFR) (1) Mesothelioma (12) Non-Small Cell Lung Cancer (NSCLC) (687) Early Stage NSCLC (Stage I/II) (98) Stage III/Locally Advanced NSCLC (172) Resectable locally advanced NSCLC (51) Unresectable locally advanced NSCLC (57) Stage IV/Advanced/Metastatic NSCLC (392) First-line treatment (197) Maintenance therapy (32) Second-line treatment (157) Third-line therapy and beyond (80) Small Cell Lung Cancer (SCLC) (101) Extensive Disease Small Cell Lung Cancer.